logo

For the Inventor, By the Inventor

Wilmington, DE, United States of America

Incyte Corporation


USPTO Granted Patents = 666



Trademarks = 8

Forward Citations = 10,160

Loading Chart...
Loading Chart...

367 inventors (with patents filed for the assignee):

goldMedal Wenqing Yao (216 out of 221 patents)

silverMedal Andrew Paul Combs (114 out of 127 patents)

bronzeMedal Liangxing Wu (110 out of 110 patents)

4.  Yun-Long Li (89 out of 96 patents)

5.  Jincong Zhuo (71 out of 76 patents)

6.  Chunhong He (70 out of 72 patents)

7.  Jiacheng Zhou (62 out of 85 patents)

8.  Richard B Sparks (62 out of 63 patents)

9.  James David Rodgers (62 out of 86 patents)

10.  Eddy W Yue (61 out of 68 patents)

11.  Stacey Shepard (56 out of 58 patents)

12.  Brian Walter Metcalf (55 out of 87 patents)

13.  Zhongjiang Jia (47 out of 48 patents)

14.  Ding-Quan Qian (47 out of 47 patents)

15.  Wenyu Zhu (44 out of 44 patents)


Core Competencies:
JAK Inhibitors
Immunomodulators
KRAS Inhibitors
BET Inhibitors
PD-1 Antibodies
PI3K Inhibitors
Combination Therapy
Heterocyclic Compounds
FGFR Inhibitors
Crystalline Forms
Biomarkers
Topical Treatments

666 patents:

1. 12498382 - Biomarkers for vitiligo (2025-12-16),
2. 12479851 - Process and intermediates for preparing a JAK inhibitor (2025-11-25),
3. 12466822 - Heterocyclic compounds as immunomodulators (2025-11-11),
4. 12466815 - Carboxamide compounds and uses thereof (2025-11-11),
5. 12459943 - Crystalline solid forms of a BET inhibitor (2025-11-04),
6. 12448448 - Anti-PD-1 antibodies and uses thereof (2025-10-21),
7. 12441742 - Naphthyridine compounds as inhibitors of KRAS (2025-10-14),
8. 12441731 - Pyrazolopyrimidine compounds and uses thereof (2025-10-14),
9. 12441727 - Tricyclic compounds as inhibitors of KRAS (2025-10-14),
10. 12440495 - Combination therapy for treatment of myeloproliferative neoplasms (2025-10-14),
11. 12428426 - Process and intermediates for preparing a JAK1 inhibitor (2025-09-30),
12. 12428420 - Tricyclic heterocycles as FGFR inhibitors (2025-09-30),
13. 12427154 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2025-09-30),
14. 12421197 - Aminopyrazine derivatives as PI3K-γ inhibitors (2025-09-23),
15. 12415809 - Pyrrolotriazine compounds as tam inhibitors (2025-09-16),
Incyte is a global biopharmaceutical company that is focused on discovering, developing, and delivering innovative medicines to patients with cancer. They work towards advancing health outcomes and improving the lives of patients through their research and development efforts. Incyte is dedicated to discovering breakthrough treatments through their expertise in molecular biology, functional genomics, medicinal chemistry, and clinical development. With a diverse portfolio of investigational and approved therapies, Incyte strives to make a positive impact on the lives of patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
666 Patents

#12 in Wilmington, DE

#16 in Delaware

#727 in US

#1,455 in the World

...
Wilmington, DE, United States of America

Incyte Corporation

Forward Citations = 10,160

367 inventors:

goldMedal Wenqing Yao (216 out of 221 patents)

silverMedal Andrew Paul Combs (114 out of 127 patents)

bronzeMedal Liangxing Wu (110 out of 110 patents)

4.  Yun-Long Li (89 out of 96 patents)

5.  Jincong Zhuo (71 out of 76 patents)

Please report any incorrect information to support@idiyas.com
Loading…